Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis - 24/04/13
Reprint requests: Alice Gottlieb, MD, PhD, Department of Dermatology, Tufts Medical Center, 800 Washington St, Box 114, Boston, MA 02111.Abstract |
Background |
Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination.
Objective |
We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone.
Methods |
In this randomized, double-blinded, multicenter 7-arm bilateral comparison-controlled trial, patients were randomized to two of 7 treatments–placebo, calcipotriene 0.005% alone, nicotinamide 1.4% alone, calcipotriene plus nicotinamide 0.05%, calcipotriene plus nicotinamide 0.1%, calcipotriene plus nicotinamide 0.7%, or calcipotriene plus nicotinamide 1.4%–each administered to lesions on one side of the body or to one of two lesions at least 5 cm apart, for 12 weeks. Efficacy was measured using a clear to almost clear outcome.
Results |
In all, 50.0% of patients in the calcipotriene and nicotinamide 1.4% combination group achieved a clear to almost clear outcome at week 12, compared with only 18.8% of patients treated with placebo (P = .002), 25% of patients treated with nicotinamide 1.4% alone (P = .02), and 31.5% of patients treated with calcipotriene alone (P = .096). A dose-response trend existed for increasing concentrations of nicotinamide, but it was not significant.
Limitations |
The relatively small patient numbers, relatively high placebo effect, and maximum in-life portion of only 12 weeks of dosing are weaknesses of the study.
Conclusion |
This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment.
Le texte complet de cet article est disponible en PDF.Key words : calcipotriene, nicotinamide, psoriasis, topical psoriasis treatment, randomized control trial
Plan
| Supported by Dermipsor Ltd. |
|
| Disclosure: Almost all of Dr Gottlieb’s income is paid to her employer directly. Dr. Gottlieb serves on speakers bureaus for Amgen Inc and Wyeth Pharmaceuticals; she has consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott Laboratories, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, Dermipsor, Can-Fite, Incyte, Corgentech, Pure-Tech, Magen Biosciences, and Cytokine Pharmasciences Inc; and she is the recipient of research/educational grants from Centocor, Amgen, Wyeth Pharmaceuticals, Immune Control, Celgene, Incyte, Abbott Laboratories, Pfizer, and NovoNordisk. Members of Dr Lebwohl’s department own patents on short-contact tazarotene, topical genistein, and use of the excimer laser for vitiligo; he serves on speakers bureaus for Abbott Laboratories, Amgen Inc, Centocor, Galderma, Genentech, PharmaDerm, Stiefel, and Warner Chilcott; he has advisory board agreements with Abbott Laboratories, Amgen Inc, Astellas, Centocor Inc, Galderma, Genentech, Medicis, Novartis, Stiefel, and Warner Chilcott; he is a consultant for Dermipsor, PharmaDerm, Sanofi-Aventis, Triax, and York Pharma. Dr Even-Chen is an employee of Dermipsor. Ms Levine, Ms Lipets, Dr Pritulo, Dr Svyatenko, and Dr Andrashko have no conflicts of interest to declare. |
Vol 63 - N° 5
P. 775-781 - novembre 2010 Retour au numéro
Article précédent
- Intermittent etanercept therapy in pediatric patients with psoriasis
- Elaine C. Siegfried, Lawrence F. Eichenfield, Amy S. Paller, David Pariser, Kara Creamer, Gregory Kricorian
- Underestimated clinical features of postadolescent acne
- Bruno Capitanio, Jo Linda Sinagra, Valentina Bordignon, Paola Cordiali Fei, Mauro Picardo, Christos C. Zouboulis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?